Licensing Deal Trends & Benchmarks
How licensing deals are actually structured.
A live view of pharma licensing deal trends and benchmarks — upfronts, milestones, royalties and structure by phase, modality and TA.
"What deal structure should we be willing to do — and what should we walk from?"
Licensing deal headlines mislead. Real benchmarks decompose total deal value into upfront / milestones / royalties and adjust for PoS, geo rights and option features.
Licensing deal benchmarks are useful only when decomposed by structure and PoS-adjusted. Headline values mislead more often than they help.
What we’re seeing in the data.
Headline deal value misleads
PoS-adjusted real deal value is often 30–50% below headline.
Phase 2 is the inflection
Upfronts and milestones spike sharply between Phase 1 and Phase 2 proof.
Royalty structures vary widely
Tiered royalties with sales thresholds dominate; flat-rate is rare.
Geo rights split commonly
US-only, ex-US, Asia-only deals are increasingly common.
How to think about it.
-
01
Decompose deal value
Upfront / dev milestones / regulatory milestones / sales milestones / royalties.
-
02
Apply PoS adjustments
Phase- and TA-specific.
-
03
Benchmark against comp set
Same TA × phase × modality × geo.
-
04
Score structural features
Options, opt-outs, co-promote, cost-share.
-
05
Walk-away threshold
Define before negotiation.
What separates a good answer from a defensible one.
Partial disclosures — triangulate.
Hot TAs price above comp.
Asia and EM rights affect valuation.
Optionality increasingly priced separately.
Where the signal comes from.
Common questions.
How do you handle confidentiality?
Triangulate disclosed bands across comparable deals.
What’s a fair upfront?
Highly TA + phase specific — never use a flat benchmark.
Want this answered on your data?
We build decision systems on top of analyses like this — so the next question takes minutes, not weeks.
Talk to a strategist